Precision Biosciences Financials
Precision Biosciences (DTIL) reported $58.0M in revenue over the twelve months to Jun 30, 2026, up 4502.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing funds development spending as revenue volatility leaves the business reliant on capital before operations become self-funding.
The 2024 profit was not cash-backed: net income of$7.2M sat beside operating cash flow of-$58.4M . In FY2025, the company returned to a-$45.7M loss while operating cash flow reached-$65.8M , showing that the earnings swing did not change the cash-consuming model.
In FY2025, research and development exceeded revenue, at
The company funded FY2025 cash use with
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Precision Biosciences's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Precision Biosciences scores -2.76, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($214.7M) relative to total liabilities ($62.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Precision Biosciences passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Precision Biosciences reported a net loss of $45.7M while operations used $65.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Precision Biosciences reported an operating loss of $52.1M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Precision Biosciences generated $34.3M in revenue in fiscal year 2025. This represents a decrease of 50.1% from the prior year.
Precision Biosciences's EBITDA was -$50.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 122.7% from the prior year.
Precision Biosciences reported -$45.7M in net income in fiscal year 2025. This represents a decrease of 738.0% from the prior year.
Precision Biosciences earned -$3.56 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Precision Biosciences recorded an outflow of $65.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 12.3% from the prior year.
Precision Biosciences held $110.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Precision Biosciences's ROE was -49.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 62.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Precision Biosciences invested $54.2M in research and development in fiscal year 2025. This represents a decrease of 9.0% from the prior year.
Precision Biosciences invested $85K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 66.0% from the prior year.
Not reported for fiscal year 2025.
DTIL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $10.8M-68.3% | $34.2M+163.1% | $13.0M+72122.2% | $18K-37.9% | $29K-95.5% | $638K+10.8% | $576K |
| R&D Expenses | $12.4M-5.5% | $13.1M-9.4% | $14.5M-99.9% | $13.4B+104473.9% | $12.8M-6.0% | $13.6M-14.6% | $15.9M+21.6% | $13.1M |
| SG&A Expenses | $6.8M-0.5% | $6.8M-5.9% | $7.2M-99.9% | $7.3B+80189.3% | $9.1M+6.7% | $8.6M-10.7% | $9.6M+9.2% | $8.8M |
| Operating Income | -$19.2M-111.1% | -$9.1M-172.6% | $12.5M+100.1% | -$20.7B-94369.1% | -$21.9M+1.1% | -$22.1M+11.0% | -$24.8M-16.8% | -$21.3M |
| Interest Expense | $300K-3.5% | $311K-10.6% | $348K-99.9% | $362.0M+101017.3% | $358K+1.1% | $354K-9.7% | $392K+53.1% | $256K |
| Net Income | -$32.7M-77.1% | -$18.4M-191.6% | $20.1M+100.1% | -$21.8B-92468.0% | -$23.5M-14.4% | -$20.6M-15.9% | -$17.7M-8.0% | -$16.4M |
| EPS (Diluted) | -$1.26-68.0% | -$0.75 | $2.58 | -$1.84 | -$2.13+3.6% | -$2.21+19.3% | -$2.74-21.8% | -$2.25 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
DTIL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $125.9M-12.5% | $143.9M-6.8% | $154.4M-99.8% | $93.5B+85745.7% | $108.9M-12.4% | $124.4M-8.8% | $136.4M-11.0% | $153.3M |
| Current Assets | $91.5M-15.8% | $108.7M-8.5% | $118.7M-99.8% | $51.7B+73492.0% | $70.3M-14.4% | $82.1M-13.6% | $95.0M-14.1% | $110.5M |
| Cash & Equivalents | $86.1M-13.4% | $99.4M-10.3% | $110.8M-99.8% | $44.9B+71989.6% | $62.2M-19.4% | $77.2M-10.1% | $85.9M-13.0% | $98.8M |
| Accounts Receivable | $0-100.0% | $4.0M | $0-100.0% | $4.0M | $0-100.0% | $4K-98.3% | $229K+21.8% | $188K |
| Total Liabilities | $80.6M+18.9% | $67.8M+9.0% | $62.2M-99.9% | $76.9B+102573.8% | $74.9M-0.3% | $75.1M-6.2% | $80.0M-9.5% | $88.4M |
| Current Liabilities | $7.1M-7.9% | $7.8M-13.0% | $8.9M-99.9% | $15.0B+110424.8% | $13.6M+9.5% | $12.4M-17.3% | $15.0M+25.0% | $12.0M |
| Total Equity | $45.3M-40.5% | $76.1M-17.5% | $92.2M-99.4% | $16.6B+48746.0% | $34.1M-31.0% | $49.3M-12.5% | $56.4M-13.1% | $64.9M |
| Retained Earnings | -$579.3M-6.0% | -$546.6M-3.5% | -$528.2M+99.9% | -$548.3B-104034.8% | -$526.5M-4.7% | -$503.0M-4.3% | -$482.5M-3.8% | -$464.7M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
DTIL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.4M-12.6% | -$11.9M-6.1% | -$11.3M+99.9% | -$15.3B-75229.3% | -$20.3M-6.4% | -$19.1M-2.0% | -$18.7M-216.0% | -$5.9M |
| Capital Expenditures | $0-100.0% | $18K-5.3% | $19K | $0-100.0% | $2K-96.9% | $64K-34.0% | $97K+148.7% | $39K |
| Free Cash Flow | -$13.4M-12.4% | -$12.0M-6.1% | -$11.3M+99.9% | -$15.3B-75221.9% | -$20.3M-6.1% | -$19.1M-1.8% | -$18.8M-215.6% | -$6.0M |
| Investing Cash Flow | $1K+100.9% | -$114K+64.9% | -$325K-101.9% | $17.0M+141766.7% | -$12K+96.2% | -$314K-223.7% | -$97K-51.6% | -$64K |
| Financing Cash Flow | $0-100.0% | $745K-99.0% | $77.5M-95.3% | $1.7B+31201.9% | $5.3M-50.4% | $10.7M+80.5% | $5.9M+58.6% | $3.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
DTIL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -83.7%-120.3pp | 36.6% | -158976.9% | -121538.9% | -76248.3% | -3894.4% | -3693.6% |
| Net Margin | N/A | -170.2% | 58.9% | -167476.9% | -130666.7% | -70913.8% | -2781.3% | -2851.6% |
| Return on Equity | -72.1%-47.9pp | -24.2%-46.1pp | 21.8%+152.7pp | -130.9%-61.8pp | -69.1%-27.4pp | -41.7%-10.2pp | -31.5%-6.1pp | -25.3% |
| Return on Assets | -25.9%-13.1pp | -12.8%-25.9pp | 13.0%+36.3pp | -23.3%-1.7pp | -21.6%-5.1pp | -16.5%-3.5pp | -13.0%-2.3pp | -10.7% |
| Current Ratio | 12.82-1.2x | 14.02+0.7x | 13.32+9.9x | 3.45-1.7x | 5.18-1.4x | 6.62+0.3x | 6.34-2.9x | 9.22 |
| Debt-to-Equity | 1.78+0.9x | 0.89+0.2x | 0.67-3.9x | 4.62+2.4x | 2.20+0.7x | 1.52+0.1x | 1.42+0.1x | 1.36 |
| FCF Margin | N/A | -110.3% | -33.0% | -117461.5% | -112627.8% | -65917.2% | -2943.6% | -1033.2% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Precision Biosciences Ranks
Frequently Asked Questions
What is Precision Biosciences's annual revenue?
Precision Biosciences (DTIL) reported $34.3M in total revenue for fiscal year 2025. This represents a -50.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Precision Biosciences's revenue growing?
Precision Biosciences (DTIL) revenue declined by 50.1% year-over-year, from $68.7M to $34.3M in fiscal year 2025.
Is Precision Biosciences profitable?
No, Precision Biosciences (DTIL) reported a net income of -$45.7M in fiscal year 2025.
What is Precision Biosciences's EBITDA?
Precision Biosciences (DTIL) had EBITDA of -$50.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Precision Biosciences's return on equity (ROE)?
Precision Biosciences (DTIL) has a return on equity of -49.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Precision Biosciences's free cash flow?
Precision Biosciences (DTIL) recorded an outflow of $65.9M in free cash flow during fiscal year 2025. This represents a -12.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Precision Biosciences's operating cash flow?
Precision Biosciences (DTIL) recorded an outflow of $65.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Precision Biosciences's total assets?
Precision Biosciences (DTIL) had $154.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Precision Biosciences's capital expenditures?
Precision Biosciences (DTIL) invested $85K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Precision Biosciences spend on research and development?
Precision Biosciences (DTIL) invested $54.2M in research and development during fiscal year 2025.
What is Precision Biosciences's current ratio?
Precision Biosciences (DTIL) had a current ratio of 13.32 as of fiscal year 2025, which is generally considered healthy.
What is Precision Biosciences's debt-to-equity ratio?
Precision Biosciences (DTIL) had a debt-to-equity ratio of 0.67 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Precision Biosciences's return on assets (ROA)?
Precision Biosciences (DTIL) had a return on assets of -29.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Precision Biosciences's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Precision Biosciences (DTIL) held $115.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $65.8M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Precision Biosciences's Altman Z-Score?
Precision Biosciences (DTIL) has an Altman Z-Score of -2.76, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Precision Biosciences's Piotroski F-Score?
Precision Biosciences (DTIL) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Precision Biosciences's earnings high quality?
Precision Biosciences (DTIL) reported a net loss of $45.7M while operations used $65.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Precision Biosciences cover its interest payments?
Precision Biosciences (DTIL) reported an operating loss of $52.1M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Precision Biosciences?
Precision Biosciences (DTIL) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.